Q-Med AB, Medicis Pharmaceutical Corporation and Genzyme Corporation enter into Settlement Agreement

17-Feb-2011 - Sweden

On October 15, 2010 Genzyme Corporation filed a complaint in the United States District Court for the District of Massachusetts against Medicis Pharmaceutical Corporation and its affiliate Medicis Aesthetics Inc. (collectively "Medicis"), alleging that Medicis is infringing on a patent held by Genzyme by marketing Restylane®, Perlane®, Restylane®-L and Perlane®-L in the United States.

Pursuant to a license agreement with Medicis, Q-Med elected to assume the defence of Genzyme's claim.

On February 14, 2011 Q-Med, Medicis and Genzyme entered into a written settlement agreement whereby none of the parties admits any liability or wrongdoing relating to the claims in the lawsuit, and pursuant to which Genzyme has agreed to dismiss the case and release Medicis and Q-Med from any liability relating to the lawsuit, and has also agreed to a certain covenant not to sue in exchange for a lump sum payment by Q-Med to Genzyme. Medicis is not required to make any payment to Genzyme or Q-Med under the terms of the settlement agreement.

Other news from the department politics & laws

Most read news

More news from our other portals

Fighting cancer: latest developments and advances